Upload
kipp
View
40
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s P rogrammes at the University of Pécs and at the University of Debrecen Identification number : TÁMOP-4.1.2-08/1/A-2009-0011. - PowerPoint PPT Presentation
Citation preview
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat the University of Pécs and at the University of DebrecenIdentification number: TÁMOP-4.1.2-08/1/A-2009-0011
FUNCTIONAL GENOMICS 2
Beáta ScholtzMolecular Therapies- Lecture 2
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat the University of Pécs and at the University of DebrecenIdentification number: TÁMOP-4.1.2-08/1/A-2009-0011
TÁMOP-4.1.2-08/1/A-2009-0011
1.1 DEFINITIONS
1.2 ABOUT DISEASES
1.3 APPROACHES TO UNDERSTANDING DISEASE MECHANISMS
1.3.1 Gene expression is regulated in several basic ways1.3.2 Microarrays: functional genomics in cancer research1.3.3 Genetic Alterations and Disease1.3.4 Genomic microarrays
1.3.4.1 Array based comparative genome hybridization (aCGH)
The aim of this chapter is to describe the main goals, tools and techniques of functional genomics. We will discuss its contribution to the advancement of modern medicine through specific examples.
FUNCTIONAL GENOMICS 1
4
Microarrays: Functional genomics to improve cancer therapy
• Identify who is at risk (Prognosis)• Identify who will and won’t respond to each agent• Identify alternatives for patients with chemo-resistant disease• Better utilization of existing and new drugs• Strategies for unique combinations of drugs
TÁMOP-4.1.2-08/1/A-2009-011
5Holly Dressman, IGSP, Genomes 101 2007
TÁMOP-4.1.2-08/1/A-2009-011
6Holly Dressman, IGSP, Genomes 101 2007
TÁMOP-4.1.2-08/1/A-2009-011
714 cell lines
more than 50 genes
Holly Dressman, IGSP, Genomes 101 2007
TÁMOP-4.1.2-08/1/A-2009-011
8Potti et al. Nat Med 2006
TÁMOP-4.1.2-08/1/A-2009-011
9
Genomic signatures for other chemoagents - thesame rationale
Potti et al. Nat Med 2006
Gene lists forNCI-60 cell lines
TÁMOP-4.1.2-08/1/A-2009-011
10
Data for real patients (ovarian cancer)Pre-existing gene expression data from GEO database
Probability score assigned by Potti et al.Sensitivity data from the same study
Potti et al. Nat Med 2006
TÁMOP-4.1.2-08/1/A-2009-011
11
Correlationbetween oncogenicpathway activationand resistanceto chemo drugs:
Combination therapywith pathway inhibitors?
src: SU6656PI3K: LY-294002
Potti et al. Nat Med 2006
TÁMOP-4.1.2-08/1/A-2009-011
12
• It is the fundamental repository of information.
• If the same DNA aberration occurs repeatedly in tumors, how can one ignore it?
• There are powerful, general methods of assessing certain types of aberrations.
• DNA is relatively robust and can be assayedspecimens that have been treated in multiple ways,including archival tissue from hospital laboratories.
Why study DNA in tumors?TÁMOP-4.1.2-08/1/A-2009-011
13
“Point”mutation – change of one or a few bases -- leads to alteredprotein or change in expression level.
Loss of gene copy reduces expression level. (tumor suppressor loss)
Gain of gene copies increases expression level. (oncogene activation)
(De)Methylation of gene promoters (increase)decrease expressionlevel. ((oncogene) tumor suppressor)
Breaking and abnormal rejoining of DNA makes novel genes.
A Variety of Genetic Alterations Underlie DevelopmentalAbnormalities and Disease
TÁMOP-4.1.2-08/1/A-2009-011
14
Mapping of genetic aberrationTÁMOP-4.1.2-08/1/A-2009-011
15
Genomic microarrays
Description:A microarray technology that detects chromosomal abnormalities
Uses:Clinical lab: complementary to fluorescence
in situ hybridization (FISH)Research lab: discover genetic basis of diseases
Significance:Many disorders are likely to be caused by microdeletionsand other chromosomal abnormalities that cannot bedetected by FISH. SNP arrays may offer even more resolution,and additional information (both genotype and copy number).
TÁMOP-4.1.2-08/1/A-2009-011
16
Different arrays for different purposesTÁMOP-4.1.2-08/1/A-2009-011
17
Array CGH
Array based comparative genome hybridization (CGH)Measures amount of DNA, not RNAComparison between two samples
‘Test’ sample‘Reference’ sample
High resolution1-3 Mb (whole genome array CGH), or 10-25 kb (oligo aCGH) vs 5-10
Mb (karyotyping)Speed : 3-4 days (array CGH) vs 2-4 weeks (karyotyping)
Simple DNA prep for array CGH instead of metaphase synchronization
TÁMOP-4.1.2-08/1/A-2009-011
18
Array CGH
Detecting genomic rearrangements found in cancer (tumor genome vs normal genome)
Study of genomic copy number variationSegregating variants found in the populationPathogenic variants associated with some disease
Compare ‘affected’ vs ‘control’ individualsUse of known probes linked to genetic markers allows better
understanding of disorders
TÁMOP-4.1.2-08/1/A-2009-011
19
Array CGH Maps DNA Copy NumberAlterations to Positions in the Genome
position on sequence
TÁMOP-4.1.2-08/1/A-2009-011
20
Array CGH Analysis of a Tumor GenomeTÁMOP-4.1.2-08/1/A-2009-011
21
• Selection for alterations in gene expression that favortumor development. Selective advantage to maintain setof aberrations.
• Mechanisms of genetic instability promoting changes inthe genome. (initiating oncogenetic event in murinemodels and methotrexate resistance in MMR deficientand proficient cell lines)
Tumor copy number profiles are a reflection of two processes
TÁMOP-4.1.2-08/1/A-2009-011
22
• Based on the results better tests can be performed that measure theDNA copy number of oncogenes and TSGs.
• Monitor cancer progression and distinguish between mild andmetastatic cancerous lesions using FISH (Florescence in situhybridization) probes on regions of recurrent copy numberaberrations in several tumor types.
• It can be used to reveal more regional copy number markers thatcan be used for cancer prediction.
• Identifying and understanding the genes that are involved in cancerwill help to design therapeutic drugs that target the dysfunctiongenes and/or avoid therapies that cause tumor resistance.
Benefits of aCGH in cancer researchTÁMOP-4.1.2-08/1/A-2009-011
23
Alterations in Cancer Cell Line Genome:Alignment of Chromosomal and Microarray Based CGH
Amplifications: Activated oncogenic genesDeletions: Inactivated (tumor suppressor) genes
TÁMOP-4.1.2-08/1/A-2009-011
24
The power of SNP arrays: Copy number silent LOH discovery
Tan DSP et al. Laboratory Investigation 2007. 87:737
TÁMOP-4.1.2-08/1/A-2009-011
25
SNP repositories
dbSNP at NCBIhttp://www.ncbi.nlm.nih.gov/SNP
Human SNP database (Whitehead Institute)http://www.broad.mit.edu/tools/data/genvar.html
The SNP Consortium (TSC)http://snp.cshl.org
J Pevsner: Bioinformatics and functional genomics
TÁMOP-4.1.2-08/1/A-2009-011
26
TÁMOP-4.1.2-08/1/A-2009-011
27
Top-bottom approachto identify novel therapeutic targets
Tan DSP et al. Pathobiology 2008. 75:63
TÁMOP-4.1.2-08/1/A-2009-011
28
Bottom-up approachto identify novel therapeutic targets
Tan DSP et al. Pathobiology 2008. 75:63
TÁMOP-4.1.2-08/1/A-2009-011
29
aCGH analysis of multiple myeloma
Carrasco DR et al. Cancer Cell 2006. 9:313
55 MM cell lines, 73 patient samples
TÁMOP-4.1.2-08/1/A-2009-011
30
nonhyperdiploid: k3,k4
hyperdiploid: k1, k2
Carrasco DR et al. Cancer Cell 2006. 9:313
Conclusion:
ch11 gain : better outcomech1q gain: worsech13 loss: worse
aCGH analysis of multiple myeloma: Prognostic classification
TÁMOP-4.1.2-08/1/A-2009-011
31
Carrasco DR et al. Cancer Cell 2006. 9:313
Combined gene expression and aCGH analysis of multiple myeloma
TÁMOP-4.1.2-08/1/A-2009-011
32
aCGH analysis of squamous cell lung cancer
Boelens MC et al. Lung Cancer 2009. 66:372
PIK3CA3q26.2-q27.3
A: All samples
B: High CNAs
TÁMOP-4.1.2-08/1/A-2009-011
33
aCGH analysis of squamous cell lung cancer:Correlation of PIK3CA expression levels and
gene amplification
Boelens MC et al. Lung Cancer 2009. 66:372
Novel therapeutic target?
TÁMOP-4.1.2-08/1/A-2009-011
34
The PIK3/Akt/mTOR signalling pathwayTÁMOP-4.1.2-08/1/A-2009-011
35
Profiles of PI3K inhibitors in clinical trial
Ihle N T , Powis G Mol Cancer Ther 2009;8:1-9
TÁMOP-4.1.2-08/1/A-2009-011